246 related articles for article (PubMed ID: 28336955)
1. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
Kim KH; Kim H
Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of a humanized neutralizing antibody targeting HGF.
Kim H; Hong SH; Kim JY; Kim IC; Park YW; Lee SJ; Song SW; Kim JJ; Park G; Kim TM; Kim YH; Park JB; Chung J; Kim IH
Exp Mol Med; 2017 Mar; 49(3):e309. PubMed ID: 28336956
[TBL] [Abstract][Full Text] [Related]
3. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
4. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
5. A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet.
Kim K; Hur Y; Ryu EK; Rhim JH; Choi CY; Baek CM; Lee JH; Chung J
Biochem Biophys Res Commun; 2007 Mar; 354(1):115-21. PubMed ID: 17214965
[TBL] [Abstract][Full Text] [Related]
6. The emerging role of MET/HGF inhibitors in oncology.
Scagliotti GV; Novello S; von Pawel J
Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
[TBL] [Abstract][Full Text] [Related]
7. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
8. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
9. Targeting the hepatocyte growth factor-cMET axis in cancer therapy.
Blumenschein GR; Mills GB; Gonzalez-Angulo AM
J Clin Oncol; 2012 Sep; 30(26):3287-96. PubMed ID: 22869872
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
[TBL] [Abstract][Full Text] [Related]
12. Targeting c-MET/HGF signaling pathway in upper gastrointestinal cancers: rationale and progress.
Gholamin S; Fiuji H; Maftouh M; Mirhafez R; Shandiz FH; Avan A
Curr Drug Targets; 2014; 15(14):1302-11. PubMed ID: 25382190
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
14. The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.
Moran-Jones K
Mol Diagn Ther; 2016 Jun; 20(3):199-212. PubMed ID: 27139908
[TBL] [Abstract][Full Text] [Related]
15. cMet agonistic antibody attenuates apoptosis in ischaemia-reperfusion-induced kidney injury.
An JN; Li L; Lee J; Yu SS; Lee J; Kim YC; Kim DK; Oh YK; Lim CS; Kim YS; Kim S; Yang SH; Lee JP
J Cell Mol Med; 2020 May; 24(10):5640-5651. PubMed ID: 32239661
[TBL] [Abstract][Full Text] [Related]
16. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
17. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
18. A receptor-antibody hybrid hampering MET-driven metastatic spread.
Modica C; Basilico C; Chiriaco C; Borrelli N; Comoglio PM; Vigna E
J Exp Clin Cancer Res; 2021 Jan; 40(1):32. PubMed ID: 33446252
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
20. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
